You are here

  • Home
  • Archive
  • Volume 4, Issue 1
  • Single dose denileukin diftitox does not enhance vaccine-induced T cell responses or effectively deplete Tregs in advanced melanoma: immune monitoring and clinical results of a randomized phase II trial

Citation Tools

Article menu

Download PDFPDF

Research Article
Single dose denileukin diftitox does not enhance vaccine-induced T cell responses or effectively deplete Tregs in advanced melanoma: immune monitoring and clinical results of a randomized phase II trial

Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

Cite this article as:
Luke JJ, Zha Y, Matijevich K, et al
Single dose denileukin diftitox does not enhance vaccine-induced T cell responses or effectively deplete Tregs in advanced melanoma: immune monitoring and clinical results of a randomized phase II trial
Journal for ImmunoTherapy of Cancer 2016;4:35. doi: 10.1186/s40425-016-0140-2